Journal
ACS NANO
Volume 15, Issue 11, Pages 18214-18225Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsnano.1c07166
Keywords
sialic acid; molecular imprinting; cell recognition; drug delivery; cancer therapy
Categories
Funding
- National Natural Science Foundation of China [21834003]
- National Key R&D Program of China [2018YFC0910301]
- Ministry of Science and Technology of China
- [ZYJH004]
Ask authors/readers for more resources
The study introduces a novel protein delivery strategy using sialic acid-imprinted biodegradable silica nanoparticles, showing targeted cancer therapy potential by effectively encapsulating cytotoxic protein RNase A. The nanovectors exhibited specific tumor-targeting ability and enhanced cell cytotoxicity, providing a promising platform for biomacromolecule delivery in cancer therapy.
Although protein therapeutics is of significance in therapeutic intervention of cancers, controlled delivery of therapeutic proteins still faces substantial challenges including susceptibility to degradation and denaturation and poor membrane permeability. Herein, we report a sialic acid (SA)-imprinted biodegradable silica nanoparticles (BS-NPs)-based protein delivery strategy for targeted cancer therapy. Cytotoxic ribonuclease A (RNase A) was effectively caged in the matrix of disulfide-hybridized silica NPs (encapsulation efficiency of similar to 64%), which were further functionalized with cancer targeting capability via surface imprinting with SA as imprinting template. Such nanovectors could not only maintain high stability in physiological conditions but also permit redox-triggered biodegradation for both concomitant release of the loaded therapeutic cargo and in vivo clearance. In vitro experiments confirmed that the SA-imprinted RNase A@BS-NPs could selectively target SA-overexpressed tumor cells, promote cells uptake, and subsequently be cleaved by intracellular glutathione (GSH), resulting in rapid release kinetics and enhanced cell cytotoxicity. In vivo experiments further confirmed that the SA-imprinted RNase A@BS-NPs had specific tumor-targeting ability and high therapeutic efficacy of RNase A in xenograft tumor model. Due to the specific targeting and traceless GSH-stimulated intracellular protein release, the SA-imprinted BS-NPs provided a promising platform for the delivery of biomacromolecules in cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available